Each of the immunoconjugate preparations were radiolabeled with 111In and their characteristics compared.
If the immunoconjugate dose is insufficient, or if the radiolabelled ligand is injected too late, clearance of the immunoconjugate results in its wash-out from tumours and consequently the uptake of radioactivity in the tumour is reduced.
Animals were then given intraperitoneal injections of the immunoconjugate (0.5 mg kg-1).
After intravenous administration of the immunoconjugate, tomographic images were obtained at 24 h.
The stability and biodistribution of the immunoconjugate labelled with Zr via the novel tris(hydroxypyridinone) ligand were compared with those of a trastuzumab immunoconjugate labelled with Zr via a H3DFO ligand.
The HAMA response, or more precisely the anti-IT antibody response, results in neutralisation of the immunoconjugate, rendering the treatment inefficacious, thus limiting the efficacy of repeated administration of the treatment.
SS was responsible for the synthesis and (radio) pharmacological evaluation of the immunoconjugates.
Such dendritic molecules will allow studies to understand the relationship between the drug/antibody ratio and the potency of the immunoconjugates.
The human-anti-IT response results in neutralisation of the immunoconjugates, rendering repetitive treatment inefficacious.
All of the immunoconjugates were purified using size exclusion chromatography, and a cumulative yield of 84.8 ± 8.4% was obtained over the course of the three step procedure (n = 20).
